Breast cancer is a malignant cell growth in the breast. Breast cancer can begin in different areas of the breast — the ducts, the lobules, or in some cases, the tissue. Sign of breast cancer include lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the nipple etc. Breast cancer most commonly develops in cell from the lining of milk ducts and the lobules that supply the ducts with milk. Cancers developing from the ducts are known as ductal carcinomas, while those developing from lobules are known as lobular carcinomas. Breast cancer is the most common cancer among women worldwide and the second-most common cancer overall. Incidence of breast cancer rise after the age 50 who have been through the menopause. About 8 out of 10 cases of breast cancer occur in women over the age of 50. Diagnosis of breast cancer is confirmed by physical examination, imaging test, or taking biopsy.
Breast cancer market is driven by increasing incidence of cancer cases (% increase in elder women in all countries) across globe. Moreover, increasing awareness, government initiative, and improved health care facilities influence the breast cancer drug market. However, high cost of treatment and limited awareness are major restraining factors in the growth of breast cancer drug market over the years. Nonetheless, ongoing research and development in the healthcare sector coupled with advancement in medical technologies is expected to open growth avenues for the market over the years.
The report covers forecast and analysis of the breast cancer drug market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based on revenue (USD Million). To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the breast cancer drug market has also been included in the study. The report also analyzes several driving and restraining factors and their impact on the market during the forecast period. The study encompasses a market attractiveness analysis, wherein treatment segments are benchmarked based on their market size, growth rate and general attractiveness.
The report provides detailed segmentation of the breast cancer drug market based on treatment and region.
Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Demand has been analyzed and forecast based on the current trends for the period of six years. North America and Europe were the leading regional segments of breast cancer drug market in 2015 on account of the high number of reported cases and easy affordability of the drugs in these regions. Moreover, technological advancement and strong demand of diagnostic test would also account for market growth. The breast cancer drug market is expected to witness the highest growth in Asia-Pacific region in upcoming years due to excessive increase of health care infrastructure, growing percentage of population, and increase in disposal income among the population.
The report covers scenario including the company overviews, financial revenues of the key participants. Key players of breast cancer drug market included in report are GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Actavis, Inc., Bristol-Myers Squibb Company, Hospira, Inc., Bayer AG, Accord Healthcare, Inc. and Gilead Sciences, Inc.
This report segments the breast cancer drug market are follows:
Breast Cancer Drug Market: Treatment Segment Analysis
- Targeted therapy
- Surgery & radiation therapy
- Hormonal therapy
Breast Cancer Drug Market: Regional Segment Analysis
- North America
- Asia pacific
- Latin America
- Middle east & Africa